HC Wainwright Reaffirms “Buy” Rating for Evaxion Biotech A/S (NASDAQ:EVAX)

HC Wainwright reissued their buy rating on shares of Evaxion Biotech A/S (NASDAQ:EVAX) in a research note released on Friday morning, Benzinga reports. The firm currently has a $14.00 price objective on the stock. HC Wainwright also issued estimates for Evaxion Biotech A/S’s FY2026 earnings at $0.77 EPS.

Evaxion Biotech A/S Stock Performance

EVAX stock opened at $3.21 on Friday. The stock’s 50 day moving average price is $2.92 and its 200 day moving average price is $3.44. The firm has a market cap of $17.37 million, a P/E ratio of -0.74 and a beta of -0.28. Evaxion Biotech A/S has a 1 year low of $2.26 and a 1 year high of $13.61.

Evaxion Biotech A/S (NASDAQ:EVAX) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.14). The business had revenue of $0.15 million for the quarter, compared to the consensus estimate of $0.10 million. During the same quarter in the prior year, the company earned ($2.10) earnings per share. On average, research analysts predict that Evaxion Biotech A/S will post -0.03 earnings per share for the current year.

Institutional Trading of Evaxion Biotech A/S

A number of hedge funds have recently added to or reduced their stakes in EVAX. Invst LLC purchased a new position in shares of Evaxion Biotech A/S during the 2nd quarter worth about $156,000. LM Advisors LLC purchased a new position in Evaxion Biotech A/S during the fourth quarter worth approximately $231,000. Finally, Armistice Capital LLC raised its stake in Evaxion Biotech A/S by 6.8% during the second quarter. Armistice Capital LLC now owns 392,000 shares of the company’s stock worth $1,137,000 after purchasing an additional 25,000 shares during the period. 11.04% of the stock is owned by institutional investors and hedge funds.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers.